Conference Call and Live Audio Webcast with Slide Presentation Scheduled for
August 10, 2017, 4:30 p.m. ET
CORALVILLE, Iowa, Aug. 01, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical
company focused on the discovery and development of proprietary prodrugs, today announced that the Company will host a conference
call and live audio webcast on Thursday, August 10, 2017, at 4:30 p.m. ET, to discuss its corporate and financial results for the
second quarter of 2017.
Conference Call Information:
Interested participants and investors may access the conference call by dialing either:
- (866) 395-2480 (U.S.)
- (678) 509-7538 (international)
- Conference ID: 63587183
An audio webcast with slide presentation will be accessible via the Investor Relations section of the KemPharm website http://investors.kempharm.com/. An archive of the webcast and presentation will remain
available for 90 days beginning at approximately 5:00 p.m. ET, on August 10, 2017.
About KemPharm
KemPharm is a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs
to treat serious medical conditions through its LAT™ (Ligand Activated Therapy) platform technology. KemPharm utilizes
its LAT™ platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of pain, ADHD
and other central nervous system disorders. KemPharm’s co-lead clinical development candidates are KP415, an extended-release
prodrug of methylphenidate for the treatment of ADHD, and KP201/IR, an acetaminophen-free formulation of the company’s immediate
release abuse deterrent hydrocodone product candidate, KP201. For more information on KemPharm and its pipeline of prodrug
product candidates visit www.kempharm.com.
Investor Contacts: Jason Rando / Joshua Drumm, Ph.D. Tiberend Strategic Advisors, Inc. 212-375-2665 / 2664 jrando@tiberend.com jdrumm@tiberend.com Media Contact: Daniel L. Cohen Executive VP, Government and Public Relations KemPharm, Inc. 202-329-1825 dcohen@kempharm.com
